A Medical Device Daily

Oculus Innovative Sciences (Petaluma, California), which markets a family of products based on Microcyn Technology platform, reported that it has filed a patent application with the U.S. Patent and Trademark Office seeking protection for a breakthrough wound care device.

The patent application describes a device that delivers a Microcyn-based solution to a chronic or acute wound site and transports organic load away from the wound bed via a vacuum process. It will monitor the wound environment and deliver additional Microcyn solution to the wound when required. The device's sponge-free dressing avoids contact with the wound, thereby eliminating the common practice of repeatedly debriding otherwise healthy fibroblast as dressings are changed. Unnecessary trauma to the wound bed can hamper or delay wound healing.

CEO Hoji Alimi said, "While there have been some modest advances in wound care over the past few decades with the advent of new dressings and negative-pressure vacuum devices, a significant number of hard-to-heal wounds remain a challenge. As a result, there are more than 100,000 amputations in the U.S. alone. This device provides a novel approach to wound care by delivering the Microcyn-based solution to the wound while eliminating the practice of frequent dressing changes as is standard today. This device is designed with a focus on preserving healthy fibroblast growth within the wound bed."

In the U.S., a 510(k) clearance is typically a quicker regulatory process and may provide Oculus with a significant new market in which the Microcyn Technology can play an increased role in the management of wounds. Meanwhile, the company continues to advance its U.S. clinical program for drug approval of the Microcyn Technology in the treatment of mildly infected diabetic foot ulcers with the recent submission of a request for an End-of-Phase II meeting with the FDA.

In other patent news, CSMG Technologies (Corpus Christi, Texas) said it has received approval of its fourth U.S. patent, a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for subsidiary Live Tissue Connect's platform tissue bonding / welding technology.

The approval follows the issuance of three other U.S. patents, a European Union patent, in eight European countries, Ukraine, Canada and Australia, with 15 U.S. and international patents pending.